نتائج البحث - "Rheumatoid/drug therapy/immunology"

المصدر: Annals of the Rheumatic Diseases, 72(4), 583-589
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 72, No 4 (2013) pp. 583-9

مصطلحات موضوعية: Settore MED/16 - REUMATOLOGIA, Arthritis, Juvenile, Antirheumatic Agents/therapeutic use, DMARDs (biologic), Spondylitis, Ankylosing/drug therapy/immunology, Arthritis, Rheumatoid, chemistry.chemical_compound, Rheumatoid, Monoclonal, Immunology and Allergy, skin and connective tissue diseases, Humanized, ddc:616, Arthritis, Juvenile/drug therapy/immunology, Antirheumatic Agents, Systematic review, Antibodies, Monoclonal, Humanized/therapeutic use, Rheumatoid arthritis, Meta-analysis, musculoskeletal diseases, Ankylosing, medicine.medical_specialty, Consensus, Immunology, Rheumatoid Arthritis, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, Antibodies, Tocilizumab, Rheumatology, Internal medicine, medicine, Humans, Spondylitis, Ankylosing, Juvenile Idiopathic Arthritis, Ankylosing spondylitis, business.industry, Interleukin-6, Clinical and Epidemiological Research, medicine.disease, Arthritis, Juvenile, Arthritis, Rheumatoid/drug therapy/immunology, Interleukin-6/antagonists & inhibitors/immunology, Treatment, chemistry, business, Spondylitis

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dcd89f6b6a3c70daee2561a6377538e
https://hdl.handle.net/1887/98414

Find this article in full text from ProQuest

9

Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions

المساهمون: Smolen, J, Schoels, Mm, Nishimoto, N, Breedveld, Fc, Burmester, Gr, Dougados, M, Emery, P, Ferraccioli, G, Gabay, C, Gibofsky, A, Gomez Reino, Jj, Jones, G, Kvien, Tk, Murakami, M, Betteridge, N, Bingham C., 3rd, Bykerk, V, Choy, Eh, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert Roth, A, Sattar, N, Scholte Voshaar, M, Tanaka, Y, Trauner, M, Valentini, Gabriele, Winthrop, Kl, de Wit, M, van der Heijde, D., Ethics, Law & Medical humanities, CCA - Innovative therapy

المصدر: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, Vol. 72, No 4 (2013) pp. 482-92
Smolen, J S, Schoels, M M, Nishimoto, N, Breedveld, F C, Burmester, G R, Dougados, M, Emery, P, Ferraccioli, G, Gabay, C, Gibofsky, A, Gomez-Reino, J J, Jones, G, Kvien, T K, Murakami, M, Betteridge, N, Bingham, C O, Bykerk, V, Choy, E H, Combe, B, Cutolo, M, Graninger, W, Lanas, A, Martin-Mola, E, Montecucco, C, Ostergaard, M, Pavelka, K, Rubbert-Roth, A, Sattar, N, Scholte-Voshaar, M, Tanaka, Y, Trauner, M, Valentini, G, Winthrop, K L, de Wit, M P T & van der Heijde, D 2013, ' Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions ', Annals of the Rheumatic Diseases, vol. 72, no. 4, pp. 482-492 . https://doi.org/10.1136/annrheumdis-2012-202469
Annals of the Rheumatic Diseases, 72(4), 482-492
Annals of the Rheumatic Diseases, 72(4), 482-492. BMJ Publishing Group

مصطلحات موضوعية: musculoskeletal diseases, Settore MED/16 - REUMATOLOGIA, Immunology, MEDLINE, Arthritis, Rheumatoid Arthritis, DMARDs (biologic), Bioinformatics, Antibodies, Monoclonal, Humanized, General Biochemistry, Genetics and Molecular Biology, Arthritis, Rheumatoid, chemistry.chemical_compound, Tocilizumab, Rheumatology, medicine, Immunology and Allergy, Humans, Inflammation/drug therapy/immunology, Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects, Interleukin 6, skin and connective tissue diseases, ddc:616, Inflammation, biology, business.industry, Interleukin-6, Consensus Statement, medicine.disease, Connective tissue disease, Receptors, Interleukin-6, R1, Antirheumatic Agents/administration & dosage/adverse effects, Antirheumatic Agents, Arthritis, Rheumatoid/drug therapy/immunology, Treatment, chemistry, Interleukin-6/antagonists & inhibitors, Rheumatoid arthritis, Interleukin-6 receptor, Receptors, Interleukin-6/antagonists & inhibitors, biology.protein, Drug Monitoring, business, Drug Monitoring/methods

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b516cdda15a3cf33922cd40e482411d5
https://orca.cardiff.ac.uk/id/eprint/110231/1/482.full.pdfxuW_D,_,_py_.pdf

Find this article in full text from ProQuest

10

Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed:pooled data from 10 European registries

المؤلفون: Ronald F van Vollenhoven, Dan Nordström, Tore K Kvien, Ulrik Tarp, Piet L. C. M. van Riel, Matija Tomšič, Galina Lukina, Merete Lund Hetland, Cem Gabay, Juan J. Gomez-Reino, Karel Pavelka, Elisabeth Lie, Katerina Chatzidionysiou, Evgeny Nasonov

المصدر: Chatzidionysiou, K, Lie, E, Nasonov, E, Lukina, G, Hetland, M L, Tarp, U, Gabay, C, van Riel, P L C M, Nordström, D C, Gomez-Reino, J, Pavelka, K, Tomsic, M, Kvien, T K & van Vollenhoven, R F 2011, ' Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed : pooled data from 10 European registries ', Annals of the Rheumatic Diseases, vol. 70, no. 9, pp. 1575-80 . https://doi.org/10.1136/ard.2010.148759
Annals of the Rheumatic Diseases, Vol. 70, No 9 (2011) pp. 1575-80
Annals of the Rheumatic Diseases, 70, 9, pp. 1575-80
Annals of the Rheumatic Diseases, 70, 1575-80

مصطلحات موضوعية: Male, Placebo-controlled study, Arthritis, Antirheumatic Agents/therapeutic use, Drug Evaluation/methods, Arthritis, Rheumatoid, Antibodies, Monoclonal, Murine-Derived, 0302 clinical medicine, immune system diseases, hemic and lymphatic diseases, Immunology and Allergy, Treatment Failure, Biological Markers/blood, skin and connective tissue diseases, ddc:616, Middle Aged, Prognosis, Connective tissue disease, 3. Good health, Rheumatoid Factor/blood, Treatment Outcome, Meta-analysis, Rheumatoid arthritis, Antirheumatic Agents, Cohort, Peptides, Cyclic/immunology, Evaluation of complex medical interventions Auto-immunity, transplantation and immunotherapy [NCEBP 2], Antibodies, Monoclonal, Murine-Derived/therapeutic use, Rituximab, Biological Markers, Female, medicine.drug, musculoskeletal diseases, Adult, medicine.medical_specialty, Immunology, Peptides, Cyclic, General Biochemistry, Genetics and Molecular Biology, 03 medical and health sciences, Rheumatology, Rheumatoid Factor, Internal medicine, medicine, Rheumatoid factor, Humans, Aged, Autoantibodies, 030203 arthritis & rheumatology, business.industry, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha, medicine.disease, Arthritis, Rheumatoid/drug therapy/immunology, Drug Evaluation, business, Autoantibodies/blood, Epidemiologic Methods, Biomarkers, 030215 immunology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25826d656251c18375ac67a84d3e5ef2
https://pure.au.dk/portal/da/publications/highest-clinical-effectiveness-of-rituximab-in-autoantibodypositive-patients-with-rheumatoid-arthritis-and-in-those-for-whom-no-more-than-one-previous-tnf-antagonist-has-failed(5fa57602-0900-49ca-8f05-6934e1870cb0).html

Find this article in full text from ProQuest

تنقيح النتائج